Immune response modulation in inflammatory bowel diseases by Helicobacter pylori infection. 2023

Gabriella Feilstrecker Balani, and Mariana Dos Santos Cortez, and Jayme Euclydes Picasky da Silveira Freitas, and Fabrício Freire de Melo, and Ana Carla Zarpelon-Schutz, and Kádima Nayara Teixeira
Campus Toledo, Universidade Federal do Paraná, Toledo 85.919-899, Paraná, Brazil.

Many studies point to an association between Helicobacter pylori (H. pylori) infection and inflammatory bowel diseases (IBD). Although controversial, this association indicates that the presence of the bacterium somehow affects the course of IBD. It appears that H. pylori infection influences IBD through changes in the diversity of the gut microbiota, and hence in local chemical characteristics, and alteration in the pattern of gut immune response. The gut immune response appears to be modulated by H. pylori infection towards a less aggressive inflammatory response and the establishment of a targeted response to tissue repair. Therefore, a T helper 2 (Th2)/macrophage M2 response is stimulated, while the Th1/macrophage M1 response is suppressed. The immunomodulation appears to be associated with intrinsic factors of the bacteria, such as virulence factors - such oncogenic protein cytotoxin-associated antigen A, proteins such H. pylori neutrophil-activating protein, but also with microenvironmental changes that favor permanence of H. pylori in the stomach. These changes include the increase of gastric mucosal pH by urease activity, and suppression of the stomach immune response promoted by evasion mechanisms of the bacterium. Furthermore, there is a causal relationship between H. pylori infection and components of the innate immunity such as the NLR family pyrin domain containing 3 inflammasome that directs IBD toward a better prognosis.

UI MeSH Term Description Entries
D007113 Immunity, Innate The capacity of a normal organism to remain unaffected by microorganisms and their toxins. It results from the presence of naturally occurring ANTI-INFECTIVE AGENTS, constitutional factors such as BODY TEMPERATURE and immediate acting immune cells such as NATURAL KILLER CELLS. Immunity, Native,Immunity, Natural,Immunity, Non-Specific,Resistance, Natural,Innate Immune Response,Innate Immunity,Immune Response, Innate,Immune Responses, Innate,Immunity, Non Specific,Innate Immune Responses,Native Immunity,Natural Immunity,Natural Resistance,Non-Specific Immunity
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013270 Stomach An organ of digestion situated in the left upper quadrant of the abdomen between the termination of the ESOPHAGUS and the beginning of the DUODENUM. Stomachs
D015212 Inflammatory Bowel Diseases Chronic, non-specific inflammation of the GASTROINTESTINAL TRACT. Etiology may be genetic or environmental. This term includes CROHN DISEASE and ULCERATIVE COLITIS. Bowel Diseases, Inflammatory,Inflammatory Bowel Disease
D016480 Helicobacter pylori A spiral bacterium active as a human gastric pathogen. It is a gram-negative, urease-positive, curved or slightly spiral organism initially isolated in 1982 from patients with lesions of gastritis or peptic ulcers in Western Australia. Helicobacter pylori was originally classified in the genus CAMPYLOBACTER, but RNA sequencing, cellular fatty acid profiles, growth patterns, and other taxonomic characteristics indicate that the micro-organism should be included in the genus HELICOBACTER. It has been officially transferred to Helicobacter gen. nov. (see Int J Syst Bacteriol 1989 Oct;39(4):297-405). Campylobacter pylori,Campylobacter pylori subsp. pylori,Campylobacter pyloridis,Helicobacter nemestrinae
D016481 Helicobacter Infections Infections with organisms of the genus HELICOBACTER, particularly, in humans, HELICOBACTER PYLORI. The clinical manifestations are focused in the stomach, usually the gastric mucosa and antrum, and the upper duodenum. This infection plays a major role in the pathogenesis of type B gastritis and peptic ulcer disease. Infections, Helicobacter,Helicobacter Infection,Infection, Helicobacter

Related Publications

Gabriella Feilstrecker Balani, and Mariana Dos Santos Cortez, and Jayme Euclydes Picasky da Silveira Freitas, and Fabrício Freire de Melo, and Ana Carla Zarpelon-Schutz, and Kádima Nayara Teixeira
January 2007, Best practice & research. Clinical gastroenterology,
Gabriella Feilstrecker Balani, and Mariana Dos Santos Cortez, and Jayme Euclydes Picasky da Silveira Freitas, and Fabrício Freire de Melo, and Ana Carla Zarpelon-Schutz, and Kádima Nayara Teixeira
February 2020, Microbial pathogenesis,
Gabriella Feilstrecker Balani, and Mariana Dos Santos Cortez, and Jayme Euclydes Picasky da Silveira Freitas, and Fabrício Freire de Melo, and Ana Carla Zarpelon-Schutz, and Kádima Nayara Teixeira
March 2012, Endocrine, metabolic & immune disorders drug targets,
Gabriella Feilstrecker Balani, and Mariana Dos Santos Cortez, and Jayme Euclydes Picasky da Silveira Freitas, and Fabrício Freire de Melo, and Ana Carla Zarpelon-Schutz, and Kádima Nayara Teixeira
February 2002, Gastroenterologie clinique et biologique,
Gabriella Feilstrecker Balani, and Mariana Dos Santos Cortez, and Jayme Euclydes Picasky da Silveira Freitas, and Fabrício Freire de Melo, and Ana Carla Zarpelon-Schutz, and Kádima Nayara Teixeira
May 2016, Medicine,
Gabriella Feilstrecker Balani, and Mariana Dos Santos Cortez, and Jayme Euclydes Picasky da Silveira Freitas, and Fabrício Freire de Melo, and Ana Carla Zarpelon-Schutz, and Kádima Nayara Teixeira
November 2003, The American journal of gastroenterology,
Gabriella Feilstrecker Balani, and Mariana Dos Santos Cortez, and Jayme Euclydes Picasky da Silveira Freitas, and Fabrício Freire de Melo, and Ana Carla Zarpelon-Schutz, and Kádima Nayara Teixeira
December 2001, Scandinavian journal of gastroenterology,
Gabriella Feilstrecker Balani, and Mariana Dos Santos Cortez, and Jayme Euclydes Picasky da Silveira Freitas, and Fabrício Freire de Melo, and Ana Carla Zarpelon-Schutz, and Kádima Nayara Teixeira
November 2001, Current drug targets. Immune, endocrine and metabolic disorders,
Gabriella Feilstrecker Balani, and Mariana Dos Santos Cortez, and Jayme Euclydes Picasky da Silveira Freitas, and Fabrício Freire de Melo, and Ana Carla Zarpelon-Schutz, and Kádima Nayara Teixeira
January 1996, Scandinavian journal of gastroenterology. Supplement,
Gabriella Feilstrecker Balani, and Mariana Dos Santos Cortez, and Jayme Euclydes Picasky da Silveira Freitas, and Fabrício Freire de Melo, and Ana Carla Zarpelon-Schutz, and Kádima Nayara Teixeira
March 2024, Antibiotics (Basel, Switzerland),
Copied contents to your clipboard!